post induction chemotherapy
Showing 26 - 50 of >10,000
Tumor Neck Trial in Shanghai (docetaxel, cisplatin and 5-fluorouracil)
Recruiting
- Neoplasm Neck
- docetaxel, cisplatin and 5-fluorouracil
-
Shanghai, Shanghai, ChinaNinth People's Hospital, School of Medicine, Shanghai Jiao Tong
Oct 5, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Induction chemo plus Concurrent chemo, Concurrent chemo, IMRT)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Induction chemotherapy plus Concurrent chemotherapy
- +2 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 17, 2022
Ventricular-Arterial Coupling: A Predictor of Post-Induction
Recruiting
- Hypotension on Induction
-
Ho Chi Minh City, VietnamUniversity Medical Centre Ho Chi Minh
Aug 1, 2023
Oropharyngeal Cancer Trial in Shanghai (Toxicities reduced treatment, Conventional treatment)
Recruiting
- Oropharyngeal Cancer
- Toxicities reduced treatment
- Conventional treatment
-
Shanghai, Shanghai, ChinaEye & ENT Hospital of Fudan University
Nov 26, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou, Zhongshan, Nanning (IMRT and concurrent cisplatin, gemcitabine and cisplatin
Not yet recruiting
- Nasopharyngeal Carcinoma
- IMRT and concurrent cisplatin
- gemcitabine and cisplatin (Induction chemotherapy)
-
Guangzhou, Guangdong, China
- +3 more
Jul 30, 2023
Head Neck Cancer Trial in Washington (Cisplatinum, Docetaxel, Carboplatin)
Active, not recruiting
- Head and Neck Cancer
- Cisplatinum
- +3 more
-
Washington, District of ColumbiaGeorge Washington University-Medical Faculty Associates
Nov 14, 2022
Laryngeal Cancer, Hypopharyngeal Cancer Trial in Shanghai (Toripalimab)
Recruiting
- Laryngeal Cancer
- Hypopharyngeal Cancer
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jun 12, 2022
Acute Myeloid Leukemia, MDS Trial in Ulm (drug, combination product, other)
Recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Venetoclax
- +4 more
-
Berlin, Germany
- +9 more
Jan 13, 2023
Colon Tumor Trial in Hangzhou (Oxaliplatin, Capecitabine, Anti-PD-L1 Monoclonal Antibody)
Not yet recruiting
- Colon Neoplasm
- Oxaliplatin
- +4 more
-
Hangzhou, Zhejiang, ChinaSecond Affiliated Hospital of Zhejiang University School of Medi
Jun 25, 2023
Postprandial Hypotension and Post-induction Hypotension in
Recruiting
- Postprandial Hypotension
- Post-induction Hypotension
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Oct 7, 2022
NSCLC Trial in Changsha (Sugemalimab and Chemotherapy)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Sugemalimab and Chemotherapy
-
Changsha, ChinaHunan Cancer Hospital
Jul 7, 2023
Norepinephrine, Post-induction Hypotension Trial in Hangzhou (norepinephrine bitartrate)
Recruiting
- Norepinephrine
- Post-induction Hypotension
- norepinephrine bitartrate
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital of Zhejiang University Medical Co
Nov 28, 2022
Head Neck Cancer Trial in Beijin (anti-PD-1 or PD-L1 antibody, postoperative radiaotherapy)
Recruiting
- Head and Neck Cancer
- anti-PD-1 or PD-L1 antibody
- postoperative radiaotherapy
-
Beijin, Beijing, ChinaNational Cancer Center /National Clinical Research Center for Ca
Mar 18, 2023
Acute Lymphocytic Leukemia Trial (Inotuzumab ozogamicin)
Not yet recruiting
- Acute Lymphocytic Leukemia
- Inotuzumab ozogamicin
- (no location specified)
Jul 11, 2022
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy Trial in Guangzhou (Toripalimab,
Not yet recruiting
- Muscle-Invasive Bladder Carcinoma
- +2 more
- Toripalimab
- +4 more
-
Guangzhou, Guangdong, ChinaCancer Center, Sun Yat-sen University
Aug 3, 2023
Acute Myeloid Leukemia (AML) Trial in Austria, Italy, Spain (Ivosidenib Oral Tablet, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia (AML)
- Ivosidenib Oral Tablet
- Azacitidine
-
Vienna, Austria
- +3 more
Jun 8, 2023
Local Advanced NSCLC Trial (Toripalimab, Radical thoracic radiotherapy)
Not yet recruiting
- Local Advanced Non-small Cell Lung Cancer
- Toripalimab
- Radical thoracic radiotherapy
- (no location specified)
Jun 2, 2023
Lung Cancer, Non-small Cell Trial in Nanjing (hypofractionated radiation therapy)
Active, not recruiting
- Lung Cancer, Non-small Cell
- hypofractionated radiation therapy
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Mar 13, 2023
Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan Universtiy Shanghai Cancer Centre
Mar 6, 2023
Conscripts, Military Induction Board, ENT Disease Trial
Not yet recruiting
- Conscripts
- +8 more
- (no location specified)
Oct 23, 2023
Esophageal Carcinoma Trial in Rochester (mFOLFOX6, Chemoradiation)
Active, not recruiting
- Esophageal Carcinoma
- mFOLFOX6
- Chemoradiation
-
Rochester, New YorkUniversity of Rochester
Aug 17, 2022
Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium
Completed
- Head and Neck Squamous Cell Carcinoma
- Apatinib Mesylate Tablets
- Tegafur Gimeracil Oteracil Potassium Capsules
-
Shanghai, Shanghai, ChinaShanghai ninth people's hospital
Jul 20, 2022
Laryngeal Cancer, Hypopharynx Cancer, Laryngeal Tumors Trial in Shanghai (chemo TP regimen combined with Toripalimab)
Recruiting
- Laryngeal Cancer
- +2 more
- chemotherapy TP regimen combined with Toripalimab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jan 2, 2022